Oncolytics Biotech Inc
TSX:ONC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oncolytics Biotech Inc
Cash from Financing Activities
Oncolytics Biotech Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oncolytics Biotech Inc
TSX:ONC
|
Cash from Financing Activities
CA$14.4m
|
CAGR 3-Years
42%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-7%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Cash from Financing Activities
CA$85.6m
|
CAGR 3-Years
154%
|
CAGR 5-Years
143%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Financing Activities
-$106.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Cash from Financing Activities
$117.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
6%
|
CAGR 10-Years
83%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Cash from Financing Activities
CA$76.1m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Cash from Financing Activities
$1.5m
|
CAGR 3-Years
-62%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Oncolytics Biotech Inc
Glance View
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.
See Also
What is Oncolytics Biotech Inc's Cash from Financing Activities?
Cash from Financing Activities
14.4m
CAD
Based on the financial report for Jun 30, 2025, Oncolytics Biotech Inc's Cash from Financing Activities amounts to 14.4m CAD.
What is Oncolytics Biotech Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-7%
Over the last year, the Cash from Financing Activities growth was -46%. The average annual Cash from Financing Activities growth rates for Oncolytics Biotech Inc have been 42% over the past three years , -18% over the past five years , and -7% over the past ten years .
